Curis

Curis (NASDAQ: CRIS) is the product of a three-way merger in 2000 of Pappas Capital portfolio company Reprogenesis with Creative Biomolecules and Ontogeny. The company was initially focused on regenerative medicine, but has evolved to become a leader in targeting signaling pathways – especially those involved in different cancers. The company’s so-called Hedgehog pathway inhibitor vismodegib is now being marketed in collaboration with Genentech.

Curis

Lexington, MA

NASDAQ

CRIS